As­traZeneca looks to re­bound from pro­duc­tion de­lays for its Covid-19 vac­cine with new fill-fin­ish deal

The re­la­tion­ship be­tween As­traZeneca and the EU has been on edge in re­cent weeks af­ter pro­duc­tion de­lays have scut­tled roll­out plans for the British drug­mak­er’s Covid-19 vac­cine. Now, look­ing to squash wor­ries its pro­duc­tion can’t keep up with de­mand, As­traZeneca is bring­ing on a new part­ner it hopes can right the ship.

As­traZeneca has tapped Ger­many’s IDT Bi­ologi­ka to ramp up im­me­di­ate pro­duc­tion of its ade­n­ovirus-based Covid-19 vac­cine, dubbed “Covid-19 Vac­cine As­traZeneca,” and build long-term ca­pac­i­ty to han­dle fill-fin­ish work for the shot, the British drug­mak­er said Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.